摘要
Purpose Despite the therapeutic success of existing HER2-targeted therapies, tumors respond quite differently to them. This study aimed at figuring out genetic mutation profile of Chinese HER2-positive patients and investigating predictive factors of neoadjuvant anti-HER2 responses. @@@ Methods We employed two cohorts. The first cohort was comprised of 181 HER2-positive patients treated at Guangdong Provincial People's Hospital from 2012 to 2018. The second cohort included 40 patients from the first cohort who underwent HER2-targeted neoadjuvant chemotherapy. Genetic mutations were characterized using next-generation sequencing. We employed the most commonly used definition of pathological complete response (pCR)-eradication of tumor from both breast and lymph nodes (ypT0/is ypN0). @@@ Results In Chinese HER2-positive breast cancer patients, TP53 (74.6%), CDK12 (64.6%) and PIK3CA (46.4%) have the highest mutation frequencies. In cohort 2, significant differences were found between pCR and non-pCR groups in terms of the initial Ki67 status, TP53 missense mutations, TP53 LOF mutations, PIK3CA mutations and ROS1 mutations (p = 0.028, 0.019, 0.005, 0.013, 0.049, respectively). Furthermore, TP53 LOF mutations and initial Ki67 status (OR 7.086, 95% CI 1.366-36.749,p = 0.020 and OR 6.007, 95% CI 1.120-32.210,p = 0.036, respectively) were found to be predictive of pCR status. @@@ Conclusion TP53 LOF mutations and initial Ki67 status in HER2-positive breast cancer are predictive of pCR status after HER2-targeted NACT.
学科与关键词
- Heterogeneity of genomic profile in patients with HER2-positive breast cancerBo Chen; Zhang, Guochun; Wei, Guangnan; Wang, Yulei; Guo, Liping; Lin, Jiali; Kai Li; Mok, Hsiaopei; Li Cao; Ren, Chongyang; Wen, Lingzhu; Jia, Minghan; Li, Cheukfai; Ting Hou; Han Han-Zhang; Jing Liu; Balch, Charles M.; Ning Liao*Endocrine-Related Cancer, 2020, 27(3): 153-162.被引 22
- Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 statusZhang, Guochun; Ren, Chongyang; Li, Cheukfai; Wang, Yulei; Chen, Bo; Wen, Lingzhu; Jia, Minghan; Li, Kai; Mok, Hsiaopei; Cao, Li; Chen, Xiaoqing; Lin, Jiali; Wei, Guangnan; Li, Yingzhi; Zhang, Yuchen; Balch, Charles M.; Liao, Ning*BMC Medicine, 2022, 20(1): 142.被引 47
- Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlationsLi, Kai; Cao, Li; Li, Cheukfai; Wu, Jundong; Chen, Bo; Zhang, Guochun; Li, Xueri; Wen, Lingzhu; Jia, Minghan; Wei, Guangnan; Lin, Jiali; Li, Yingzi; Zhang, Yuchen; Mok, Hsiaopei; Ren, Chongyang; Wang, Yulei; Qi, Xiaofang; Guo, Lijie; Che, Yue; Liao, Ning*Cancer Medicine, 2023, 12(5): 5195-5208.
